Skip to main content
Erschienen in: Medical Oncology 2/2011

01.06.2011 | Original Paper

Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer

verfasst von: Shi-Lian Hu, Da-Bing Huang, Yu-Bei Sun, Lei Wu, Wei-Ping Xu, Shi Yin, Jiong Chen, Xiao-Dong Jiang, Gan Shen

Erschienen in: Medical Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Runx3 and CHFR genes were defined as tumor suppressor genes in gastric cancer (GC) recently. This paper was to investigate the roles of methylation and expression status of Runx3 and CHFR genes in GC patients. Methylation-specific polymerase chain reaction (MSP) and bisulfite DNA sequencing (BSP) were used to detect methylation status of Runx3 and CHFR genes in GC patients. The expression of Runx3 and CHFR in GC patients was analyzed by reverse transcription polymerase chain reaction (RT–PCR) and immunohistochemical analysis. The expression of the protein and mRNA decreased remarkably in the patients with aberrant promoter methylation of Runx3 and CHFR genes. The methylation status of Runx3 and CHFR were inversely related to the tumor size, tumor invasion depth and tumor differentiation in GC patients. Moreover, the protein expression of Runx3 and CHFR were significantly correlated with tumor invasion depth and tumor differentiation, respectively. Aberrant promoter methylation of Runx3 and CHFR genes may be involved in the carcinogenesis and development of GC and may provide useful clues for the prediction of the malignant behaviors of GC.
Literatur
1.
Zurück zum Zitat Machado JC, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525–8.PubMedCrossRef Machado JC, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525–8.PubMedCrossRef
2.
Zurück zum Zitat Lee TL, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 2002;8:1761–6.PubMed Lee TL, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 2002;8:1761–6.PubMed
3.
Zurück zum Zitat Leung WK, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer. 2005;92:2190–4.PubMedCrossRef Leung WK, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer. 2005;92:2190–4.PubMedCrossRef
4.
Zurück zum Zitat Oue N, et al. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol. 2002;198:55–9.PubMedCrossRef Oue N, et al. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol. 2002;198:55–9.PubMedCrossRef
6.
Zurück zum Zitat Kim TY, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004;84:479–84.PubMedCrossRef Kim TY, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004;84:479–84.PubMedCrossRef
7.
Zurück zum Zitat Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology. 2008;75:244–51.PubMedCrossRef Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology. 2008;75:244–51.PubMedCrossRef
8.
Zurück zum Zitat Subramaniam MM, et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 2009;113:113–21.PubMedCrossRef Subramaniam MM, et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat. 2009;113:113–21.PubMedCrossRef
9.
Zurück zum Zitat Nishida N, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008;47:908–18.PubMedCrossRef Nishida N, et al. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008;47:908–18.PubMedCrossRef
10.
Zurück zum Zitat Li QL, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113–24.PubMedCrossRef Li QL, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113–24.PubMedCrossRef
11.
Zurück zum Zitat Toyota M, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA. 2003;100:7818–23.PubMedCrossRef Toyota M, et al. Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA. 2003;100:7818–23.PubMedCrossRef
12.
Zurück zum Zitat Corn PG, et al. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis. 2003;24:47–51.PubMedCrossRef Corn PG, et al. Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis. 2003;24:47–51.PubMedCrossRef
13.
Zurück zum Zitat Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000;406:430–5.PubMedCrossRef Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000;406:430–5.PubMedCrossRef
14.
Zurück zum Zitat Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed. International Union Against Cancer (UICC): New York; 1997. Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th ed. International Union Against Cancer (UICC): New York; 1997.
15.
Zurück zum Zitat Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–6.PubMedCrossRef
16.
Zurück zum Zitat Shibata Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002;23:1695–9.PubMedCrossRef Shibata Y, et al. Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis. 2002;23:1695–9.PubMedCrossRef
17.
Zurück zum Zitat Homma N, et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 2006;97:51–6.PubMedCrossRef Homma N, et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 2006;97:51–6.PubMedCrossRef
18.
Zurück zum Zitat Gao YJ, Xin Y, Zhang JJ, Zhou J. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma. World J Gastroenterol. 2008;14:5000–7.PubMedCrossRef Gao YJ, Xin Y, Zhang JJ, Zhou J. Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma. World J Gastroenterol. 2008;14:5000–7.PubMedCrossRef
19.
Zurück zum Zitat Wang L, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed Wang L, et al. Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed
20.
Zurück zum Zitat Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer. 2006;106:483–93.PubMedCrossRef Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer. 2006;106:483–93.PubMedCrossRef
21.
Zurück zum Zitat Lau QC, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66:6512–20.PubMedCrossRef Lau QC, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66:6512–20.PubMedCrossRef
22.
Zurück zum Zitat Ku JL, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 2004;23:6736–42.PubMedCrossRef Ku JL, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene. 2004;23:6736–42.PubMedCrossRef
23.
Zurück zum Zitat Tamura G. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol. 2004;19:221–8.PubMed Tamura G. Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol. 2004;19:221–8.PubMed
24.
Zurück zum Zitat Honda T, et al. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. Br J Cancer. 2004;90:2013–6.PubMedCrossRef Honda T, et al. Promoter hypermethylation of the Chfr gene in neoplastic and non-neoplastic gastric epithelia. Br J Cancer. 2004;90:2013–6.PubMedCrossRef
25.
Zurück zum Zitat Waki T, et al. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 2003;94:360–4.PubMedCrossRef Waki T, et al. Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci. 2003;94:360–4.PubMedCrossRef
26.
Zurück zum Zitat Kang HC, et al. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers. Oncol Rep. 2004;12:129–33.PubMed Kang HC, et al. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers. Oncol Rep. 2004;12:129–33.PubMed
27.
Zurück zum Zitat Morioka Y, et al. Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res. 2006;26:1791–5.PubMed Morioka Y, et al. Aberrant methylation of the CHFR gene in digestive tract cancer. Anticancer Res. 2006;26:1791–5.PubMed
28.
Zurück zum Zitat Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 2008;99:646–52.PubMedCrossRef Kim WJ, Bae SC. Molecular biomarkers in urothelial bladder cancer. Cancer Sci. 2008;99:646–52.PubMedCrossRef
29.
Zurück zum Zitat Kim EJ, et al. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008;180:1141–5.PubMedCrossRef Kim EJ, et al. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor. J Urol. 2008;180:1141–5.PubMedCrossRef
30.
Zurück zum Zitat Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res. 2007;67:6064–74.PubMedCrossRef Privette LM, Gonzalez ME, Ding L, Kleer CG, Petty EM. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression. Cancer Res. 2007;67:6064–74.PubMedCrossRef
Metadaten
Titel
Pathobiologic implications of methylation and expression status of Runx3 and CHFR genes in gastric cancer
verfasst von
Shi-Lian Hu
Da-Bing Huang
Yu-Bei Sun
Lei Wu
Wei-Ping Xu
Shi Yin
Jiong Chen
Xiao-Dong Jiang
Gan Shen
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9467-6

Weitere Artikel der Ausgabe 2/2011

Medical Oncology 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.